Summary Despite the scientific and technical capacity for precision oncology in North America (Canada, the United States, and Mexico), its implementation is deeply uneven across the region. Our narrative synthesis of precision oncology implementation found that delivery consistently fails at four operational steps: bio...
Priya Kumar, A. Salawu, R. Demichelis-Gómez et al.· The Lancet Regional Health -...· 0 citations
It is suggested that productive immunotherapy responses in PDAC require not only tumor-reactive T cells, but also a stromal-vascular niche capable of supporting their recruitment, recirculation and persistence.
Sarah Kang, M. Parikh, Leontios Pappas et al.· Cancer Research· 0 citations
Pancreatic re-RT is feasible and may offer promising local control and time off chemotherapy for selected patients, and improvements in RT delivery with online adaptive therapy may further minimize toxicity.
Helen X. Hou, Hannah J. Roberts, P. Pathak et al.· American Journal of Clinical...· 0 citations
Molecular residual disease (MRD), detected via circulating tumor DNA (ctDNA) after curative-intent surgery, identifies resectable solid tumor patients at high recurrence risk, thereby enabling enriched trials with larger effect sizes and smaller samples. Yet enrichment narrows the eligible population and thus challenge...
S. Kobayashi, T. Hashimoto, H. Bando et al.· Cancer Cell· 0 citations
The combination of immune-modulating, non-ablative doses of radiation therapy with ipilimumab and nivolumab has selective clinical activity in refractory MSS CRC, with responses concentrated primarily in patients without active liver metastases.
Leontios Pappas, J. Koenig, B. Yeap et al.· Clinical Cancer Research· 0 citations
The Commission developed a value-based resource-stratified implementation framework, a system-readiness assessment tool, a precision oncology workforce competency-based framework, a precision oncology monitoring and evaluation framework, and principles for responsible data sharing and health-system learning.
R. Casolino, J. Mateo, E. D. de Vries et al.· The Lancet Oncology· 11 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.